Rhabdomyolysis
Conditions
Interventions
Group 1: Therapy with the hemadsorber Cytosorb (Cytosorbents Europe GmbH, Berlin, Germany) during two times 24 hours plus:
Standard therapy: continuous venovenous hemodialysis with high flows (blood
Sponsors
Universitätsklinikum des Saarlandes Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie Geb. 57
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - severe rhabdomyolysis - indication for continuous renal replacement therapy in the ICU
Exclusion criteria
Exclusion criteria: - pregnancy - simultaneous participation in another study - previous participation in the same study - no informed consent obtainable - patients permanently not able to give informed consent (e.g. dementia, permanent legal representative) - contraindication to or refusal to accept hemodialysis treatment - impossibility or contraindication to implantation of a dialysis catheter - Impossibility to achieve high blood flow (200 ml/hour) through the dialysis catheter
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percent fall in myoglobin serum concentration during the first 24 hours of therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Myoglobin elimination rates will be determined by measuring myoglobin concentrations in patient blood (pre-CS), after passage through the hemadsorber (post-CS) and after passage through the hemofilter (post-Filter), as well as in patient urine and in the effluate from the hemodialysis device. It will also be examined whether the hemabsorber shows saturation kinetics for myoglobin over 24 hours. In addition, mortality and necessity of renal replacement therapy over 30 days after initiation of therapy will be monitored. | — |
Countries
Germany
Contacts
Public ContactAndreas Meiser
Universitätsklinikum des Saarlandes Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie Geb. 57
Outcome results
None listed